Hologic Inc (HOLX)
Official siteMEDICAL INSTRUMENTS & SUPPLIES
Last updated: Apr 07, 2026 at 5:00 PM ET
Hologic Inc (HOLX) Financials: Revenue, Profit and Cash Flow
Hologic reported revenue of $4.10B for the fiscal year ended Sep 30, 2025, up 1.7% from the year before. That year, net income was $565.70M with a net margin of 13.8%, operating cash flow was $1.06B and free cash flow was $920.10M. The quarter ended Dec 31, 2025 had revenue of $1.05B and net income of $179.10M.
Revenue and Margins
The operating margin was 17.4% in the fiscal year ended Sep 2025. Over the 9 years to Sep 2025, revenue grew from $2.83B, a compound annual rate of 4.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $4.10B | +1.7% | 51.6% | 17.4% | 13.8% |
| Sep 2024 | $4.03B | 0.0% | 55.3% | 21.9% | 19.6% |
| Sep 2023 | $4.03B | -17.1% | 51.4% | 16.6% | 11.3% |
| Sep 2022 | $4.86B | -13.7% | 61.6% | 33.7% | 26.8% |
| Sep 2021 | $5.63B | +49.1% | 67.4% | 44.0% | 33.2% |
| Sep 2020 | $3.78B | +12.1% | 59.0% | 29.3% | 29.4% |
| Sep 2019 | $3.37B | +4.6% | 34.8% | -3.7% | -6.0% |
| Sep 2018 | $3.22B | +5.2% | 52.7% | -7.4% | -3.5% |
| Sep 2017 | $3.06B | +8.0% | 53.0% | 44.8% | 24.7% |
| Sep 2016 | $2.83B | N/A | 55.2% | 19.4% | 11.7% |
Income Statement
In the fiscal year ended Sep 2025, net income fell 28.3% from the year before. In the quarter ended Dec 2025, net income fell 10.9% from the same quarter a year earlier.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.10B | $4.03B | $4.03B | $4.86B | $5.63B | $3.78B | $3.37B | $3.22B | $3.06B | $2.83B |
| Cost of revenue | $1.98B | $1.80B | $1.96B | $1.87B | $1.84B | $1.55B | $2.20B | $1.52B | $1.44B | $1.07B |
| Gross profit | $2.12B | $2.23B | $2.07B | $3.00B | $3.80B | $2.23B | $1.17B | $1.70B | $1.62B | $1.56B |
| Research and development | $248.20M | $272.80M | $294.30M | $283.40M | $276.30M | $222.50M | $232.20M | $218.70M | $232.80M | $232.10M |
| Operating income | $714.30M | $882.60M | $668.40M | $1.64B | $2.48B | $1.10B | -$123.80M | -$237.90M | $1.37B | $548.60M |
| Net income | $565.70M | $789.50M | $456.00M | $1.30B | $1.87B | $1.11B | -$203.60M | -$111.30M | $755.50M | $330.80M |
| EBITDA | $1.02B | $1.19B | $990.10M | $2.10B | $2.88B | $1.49B | $342.40M | $250.00M | $1.88B | $1.09B |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.05B | $1.05B | $1.02B | $1.01B | $1.02B | $988.00M | $1.01B | $1.02B | $1.01B | $945.30M | $984.40M | $1.03B |
| Gross profit | $586.40M | $583.50M | $576.60M | $377.30M | $580.50M | $557.70M | $560.30M | $542.30M | $567.50M | $500.30M | $367.50M | $585.80M |
| Operating income | $237.00M | $236.90M | $254.60M | -$7.00M | $229.80M | $230.00M | $244.00M | $210.40M | $198.20M | $132.50M | $1.40M | $272.10M |
| Net income | $179.10M | $187.20M | $194.90M | -$17.40M | $201.00M | $178.60M | $194.50M | $169.90M | $246.50M | $90.60M | -$40.50M | $218.50M |
Balance Sheet
As of Sep 2025, total debt of $2.51B exceeded cash and equivalents by $548.40M.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $9.01B | $9.16B | $9.14B | $9.07B | $8.92B | $7.20B | $6.44B | $7.23B | $7.98B | $7.32B |
| Current assets | $3.67B | $3.82B | $4.18B | $3.86B | $3.17B | $2.22B | $1.79B | $1.72B | $1.48B | $1.33B |
| Cash and equivalents | $1.96B | $2.16B | $2.72B | $0 | $0 | $701.00M | $601.80M | $666.70M | $540.60M | $548.40M |
| Total liabilities | $3.97B | $4.03B | $4.12B | $4.20B | $4.70B | $4.49B | $4.33B | $4.80B | $5.19B | $5.17B |
| Short-term debt | $2.90M | $37.50M | $287.00M | $15.00M | $313.00M | $324.90M | $273.20M | $601.40M | $1.15B | $296.00M |
| Long-term debt | $2.50B | $2.50B | $2.53B | $2.81B | $2.71B | $2.71B | $2.78B | $2.70B | $2.17B | $3.05B |
| Shareholder equity | $5.05B | $5.13B | $5.02B | $4.88B | $4.22B | $2.71B | $2.12B | $2.43B | $2.78B | $2.14B |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $9.18B | $9.01B | $8.81B | $8.55B | $8.73B | $9.16B | $8.89B | $8.71B | $8.47B | $9.14B | $9.34B | $9.45B |
| Total liabilities | $3.94B | $3.97B | $3.96B | $3.93B | $3.96B | $4.03B | $3.94B | $3.87B | $3.82B | $4.12B | $4.16B | $4.15B |
| Cash and equivalents | $2.17B | $1.96B | $1.74B | $1.43B | $1.78B | $2.16B | $2.44B | $2.18B | $1.93B | $2.72B | $2.77B | $2.58B |
| Shareholder equity | $5.25B | $5.05B | $4.84B | $4.62B | $4.77B | $5.13B | $4.95B | $4.84B | $4.65B | $5.02B | $5.18B | $5.30B |
Cash Flow
In the fiscal year ended Sep 2025, free cash flow was 86.8% of operating cash flow. Share repurchases came to 81.8% of it.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.06B | $1.29B | $1.05B | $2.13B | $2.33B | $896.60M | $649.50M | $732.90M | $8.30M | $798.20M |
| Capital expenditures | $137.00M | $130.20M | $150.20M | $127.20M | $177.70M | $156.40M | $109.10M | $105.60M | $107.60M | $94.50M |
| Free cash flow | $920.10M | $1.16B | $901.00M | $2.00B | $2.15B | $740.20M | $540.40M | $627.30M | -$99.30M | $703.70M |
| Dividends paid | N/A | N/A | N/A | N/A | $8.50M | $1.80M | $0 | $0 | $393.00M | $250.00M |
| Share repurchases | $752.90M | $835.10M | $474.80M | $542.10M | $409.80M | $653.60M | $200.10M | $275.80M | $200.10M | $250.00M |
| Investing cash flow | -$482.70M | -$781.00M | -$152.10M | -$206.30M | -$1.33B | -$141.60M | -$280.70M | -$195.20M | $285.80M | -$68.40M |
| Financing cash flow | -$777.20M | -$1.11B | -$483.20M | -$756.00M | -$529.80M | -$659.90M | -$431.50M | -$404.80M | -$309.20M | -$670.70M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $229.90M | $355.10M | $343.30M | $169.40M | $189.30M | $367.00M | $405.80M | $292.40M | $220.00M | $258.70M | $332.80M | $206.30M |
| Capital expenditures | $35.10M | $30.40M | $34.80M | $40.20M | $31.60M | $30.30M | $33.90M | $28.00M | $38.00M | $52.50M | $36.50M | $32.10M |
| Free cash flow | $194.80M | $324.70M | $308.50M | $129.20M | $157.70M | $336.70M | $371.90M | $264.40M | $182.00M | $206.20M | $296.30M | $174.20M |
Frequently Asked Questions About HOLX
What is Hologic's annual revenue?
Hologic reported revenue of $4.10B for the fiscal year ended Sep 30, 2025.
How fast is Hologic's revenue growing?
Revenue was up 1.7% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -5.5%.
Is Hologic profitable?
Yes. Hologic reported net income of $565.70M for the fiscal year ended Sep 30, 2025, with a net margin of 13.8%.
How much free cash flow does HOLX generate?
For the fiscal year ended Sep 30, 2025, operating cash flow of $1.06B minus capital expenditures of $137.00M produced free cash flow of $920.10M.
How much debt does Hologic have?
The balance sheet dated Sep 30, 2025 reported long-term debt of $2.50B, short-term debt of $2.90M and cash and equivalents of $1.96B.
HOLX pages: Overview, Financials